Cogent Biosciences submits FDA NDA for bezuclastinib in advanced systemic mastocytosisPUBT·Jun 30 at 07:02 AMCOGT+4.52%
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor BaseSimplywall·Jun 29 at 11:11 PMCOGT+4.52%
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)Tip Ranks·Jun 17 at 08:35 AMCOGT+4.52%
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressUnusual Whales·Jun 12 at 07:02 AMCOGT+4.52%
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | COGT Stock NewsStockTitan·Jun 11 at 11:01 PMCOGT+4.52%
Cogent Biosciences Shareholders Back Board, Governance ProposalsTip Ranks·Jun 11 at 04:55 PMCOGT+4.52%
Cogent Biosciences' Bezuclastinib Combo Doubles Progression-Free Survival In GISTnasdaq·Jun 1 at 02:55 AMCOGT+4.52%FBT+0.87%
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | COGT Stock NewsStockTitan·May 29 at 11:00 PMCOGT+4.52%LABU+7.13%
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GISTUnusual Whales·May 28 at 07:02 AMCOGT+4.52%
